The experience with vigabatrin as anticonvulsant add on-therapy in adults with previously pharmacotherapy-resistant seizures is reviewed on the basis of several single-blind and ten double-blind, placebo-controlled studies. Evaluation of efficacy showed an at least 50 % reduction of seizure frequency in every second patient. Longterm follow up studies demonstrated a possible loss of efficacy over time but exact data are still missing. As anticipated, the achievement of seizure-freedom in patients with so far therapy resistant epilepsies is possible in only few patients, but in several patients improvement of duration and intensity of seizures is obtained beside reduction of seizure frequency. The presently recommended standard dose is two to three g/day in a b. i. d regimen. The main side effect is sedation in about 20 % of the patients which is less often observed with slowly increasing dosages starting with 500 mg/day instead of 2 g/day initially. Possibly, psychotic side effects are observed more often with vigabatrin than with other anticonvulsants, but they are reversible after discontinuation of the drug like all other side effects. Measurements of serum level and other laboratory studies are less important as compared with other antiepileptic drugs.
Read full abstract